Meta-analysis: Octreotide prevents post-ERCP pancreatitis, but only at sufficient doses

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 11, 2009, Pages 1155-1164

  Zhang, Y ^a   Chen, Q B ^a   Gao, Z Y ^a   Xie, W F ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PLACEBO;

ABDOMINAL DISTENSION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPERAMYLASEMIA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; MEDICAL LITERATURE; META ANALYSIS; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; VOMITING;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GASTROINTESTINAL AGENTS; HUMANS; OCTREOTIDE; ODDS RATIO; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 66149105804     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03991.x     Document Type: Article

References (40)

1. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991 37 : 383 93.
2. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001 54 : 425 34. (Pubitemid 33661145)
3. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004 59 : 845 64. (Pubitemid 38879313)
4. Dumot JA, Conwell DL, Zuccaro GJ, et al. A randomized double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001 96 : 2098 102. (Pubitemid 32660903)
5. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002 56 : 202 8.
6. Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs 2003 63 : 1799 812. (Pubitemid 37083028)
7. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study? Gastrointest Endosc 2003 58 : 23 9. (Pubitemid 38208742)
8. Schwartz JJ, Lew RJ, Ahmad NA, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004 59 : 179 84. (Pubitemid 38199209)
9. Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004 59 : 606 13. (Pubitemid 38609687)
10. Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 2005 62 : 245 50. (Pubitemid 41021551)
11. Harewood GC, Topazian M. Post-ERCP pancreatitis: is allopurinol the Holy Grail? Gastrointest Endosc 2005 62 : 251 2. (Pubitemid 41021552)
12. Rudin D, Kiss A, Wetz RV, Sottile VM. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007 22 : 977 83. (Pubitemid 47019864)
13. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007 65 : 624 32. (Pubitemid 46442832)
14. Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc 1991 37 : 48 50.
15. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001 15 : 965 72. (Pubitemid 32578968)
16. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, Frangou E. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology 1998 45 : 248 52. (Pubitemid 28067562)
17. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992 87 : 1561 6.
18. Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992 33 : 1129 33.
19. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994 26 : 715 8.
20. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000 51 : 1 7. (Pubitemid 30051601)
21. Bai Y, Gao J, Zou DW, Li ZS. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008 37 : 241 6.
22. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001 135 : 982 9. (Pubitemid 33131619)
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1 12. (Pubitemid 26120810)
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 88. (Pubitemid 17189972)
25. Skordilis PG VA, Varfas E, et al. Somatostatin can be efficient for the prevention of the post-ERCP pancreatitis? [Abstract]. Endoscopy 2005 37 : A279.
26. Baldazzi G, Conti C, Spotti EG, et al. [Prevention of post-ERCP acute pancreatitis with octreotide]. G Chir 1994 15 : 359 62.
27. Armonis A, Manolakopoulos S, Papadimitrious N, Gouma P, Avgerinos A. The effect of long acting somatostatin analogue in the prevention of post-ERCP pancreatitis. Gut 1994 35 : A85.
28. Badra G, Galal AS, Rowaisha I, Waked I, Moustafa MS, Saleh SM. Allopurinol vs octreotide in the prevention of post-ERCP pancreatitis in patient with billiary obstruction. A randomized controlled trial. Hepatology 2000 32 : 163A.
29. Testoni PA, Lella F, Bagnolo F, et al. Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas 1996 13 : 61 5. (Pubitemid 26187771)
30. Tulassay Z, Dobronte Z, Pronai L, Zaqoni T, Juhasz L. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998 12 : 1109 12. (Pubitemid 28508724)
31. Russo A, Virgilio C, Aprile G. Influenza dell'octreotide sulla reazione pancreatica indotta de colangiopancreatografia retrograda. Giorn Ital End Dig 1992 15 : 139 45.
32. Duvnjak M, Supanc V, Simicevic VN, et al. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica 1999 53 : 115 8. (Pubitemid 30415475)
33. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002 55 : 470 5.
34. Thomopoulos KC, Pagoni NA, Vagenas KA, Marqaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006 64 : 726 31. (Pubitemid 44573121)
35. Li ZS, Pan X, Zhang WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007 102 : 46 51. (Pubitemid 46072042)
36. Testoni PA, Lella F, Bagndo F, Buizza M, Colombo E. Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy. Ital J Gastroenterol 1994 26 : 431 6.
37. Ng KW, Jiang CF, Liang CT, et al. A prospective, randomized, controlled trial to evaluate the effect of prophylactic sandostatin on ERCP-induced hyperamylasemia and pancreatitis. Gastroenterol J Taiwan 1997 14 : 192 7.
38. Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials Gastrointest Endosc 2004 60 : 544 50. (Pubitemid 39311536)
39. Lieb JG II., Draganov PV. Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography. World J Gastroenterol 2007 13 : 3567 74. (Pubitemid 47162263)
40. Andriulli A, Forlano R, Napolitano G, et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007 75 : 156 63. (Pubitemid 47343973)